Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 492 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 How to Safely Keep Up With Your Cancer Screening and Care... December 10, 2020 Seven Centres to form new Cancer Research UK network January 24, 2022 NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia May 23, 2022 Load more HOT NEWS TP53 Allelic State is Critical in Myelodysplastic Syndromes First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... Home Is Where the Heart Is Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated...
